-
1
-
-
0020687971
-
Metoclopramide: Pharmacology and clinical application
-
Albibi R, McCallum RW (1983) Metoclopramide: pharmacology and clinical application. Ann Intern Med 98:86-95 (Pubitemid 13217970)
-
(1983)
Annals of Internal Medicine
, vol.98
, Issue.1
, pp. 86-95
-
-
Albibi, R.1
McCallum, R.W.2
-
2
-
-
0035041926
-
Antipsychotic-induced weight gain: A review of the literature
-
Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62:22-31 (Pubitemid 32402182)
-
(2001)
Journal of Clinical Psychiatry
, vol.62
, Issue.SUPPL. 7
, pp. 22-31
-
-
Allison, D.B.1
Casey, D.E.2
-
3
-
-
0020576099
-
Clinical pharmacokinetics of metoclopramide
-
Bateman DN (1983) Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 8:523-529 (Pubitemid 13023845)
-
(1983)
Clinical Pharmacokinetics
, vol.8
, Issue.6
, pp. 523-529
-
-
Bateman, D.N.1
-
4
-
-
0030062260
-
Radioreceptor binding profile of the atypical antipsychotic olanzapine
-
DOI 10.1016/0893-133X(94)00129-N
-
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96 (Pubitemid 26053226)
-
(1996)
Neuropsychopharmacology
, vol.14
, Issue.2
, pp. 87-96
-
-
Bymaster, F.P.1
Calligaro, D.O.2
Falcone, J.F.3
Marsh, R.D.4
Moore, N.A.5
Tye, N.C.6
Seeman, P.7
Wong, D.T.8
-
5
-
-
0035798393
-
6 receptors by olanzapine
-
DOI 10.1016/S0014-2999(01)01399-1, PII S0014299901013991
-
Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, Cohen ML (2001) Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 430:341-349 (Pubitemid 33050060)
-
(2001)
European Journal of Pharmacology
, vol.430
, Issue.2-3
, pp. 341-349
-
-
Bymaster, F.P.1
Falcone, J.F.2
Bauzon, D.3
Kennedy, J.S.4
Schenck, K.5
DeLapp, N.W.6
Cohen, M.L.7
-
6
-
-
0025615002
-
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study
-
2146911 10.7326/0003-4819-113-11-834
-
De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834-840
-
(1990)
Ann Intern Med
, vol.113
, pp. 834-840
-
-
De Mulder, P.H.1
Seynaeve, C.2
Vermorken, J.B.3
Van Liessum, P.A.4
Mols-Jevdevic, S.5
Allman, E.L.6
Beranek, P.7
Verweij, J.8
-
7
-
-
84892678561
-
-
National Comprehensive Cancer Network, Inc
-
Ettinger DA, Barbour S, Berger M, Bierman P, Bradbury B, Ellis G, Kirkegaard S, Kloth D, Kris M, Lim D, Mandrell B, Michaud L, Noonan K, Rugo H, Scullion B, Sorscher S, Stucky-Marshall L, Todaro B, Urba S (2013) Antiemesis (version 1.2013). National Comprehensive Cancer Network, Inc
-
(2013)
Antiemesis (Version 1.2013)
-
-
Ettinger, D.A.1
Barbour, S.2
Berger, M.3
Bierman, P.4
Bradbury, B.5
Ellis, G.6
Kirkegaard, S.7
Kloth, D.8
Kris, M.9
Lim, D.10
Mandrell, B.11
Michaud, L.12
Noonan, K.13
Rugo, H.14
Scullion, B.15
Sorscher, S.16
Stucky-Marshall, L.17
Todaro, B.18
Urba, S.19
-
8
-
-
84868481728
-
Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients' quality of life
-
1:STN:280:DC%2BC38rgslaqsw%3D%3D 22460057 10.1007/s00520-012-1448-1
-
Fernandez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Suarez C, Zorrilla I, Gomez J, Zabaleta P, Nocea G, Llombart-Cussac A (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer 20:3141-3148
-
(2012)
Support Care Cancer
, vol.20
, pp. 3141-3148
-
-
Fernandez-Ortega, P.1
Caloto, M.T.2
Chirveches, E.3
Marquilles, R.4
Francisco, J.S.5
Quesada, A.6
Suarez, C.7
Zorrilla, I.8
Gomez, J.9
Zabaleta, P.10
Nocea, G.11
Llombart-Cussac, A.12
-
9
-
-
85027951242
-
Increased food intake and energy expenditure following administration of olanzapine to healthy men
-
1:CAS:528:DC%2BC3cXptlymsrY%3D 20134408 10.1038/oby.2010.6
-
Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA (2010) Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity 18:1646-1651
-
(2010)
Obesity
, vol.18
, pp. 1646-1651
-
-
Fountaine, R.J.1
Taylor, A.E.2
Mancuso, J.P.3
Greenway, F.L.4
Byerley, L.O.5
Smith, S.R.6
Most, M.M.7
Fryburg, D.A.8
-
10
-
-
34547872714
-
Anti-emetic therapy in cancer chemotherapy: Current status
-
DOI 10.1111/j.1742-7843.2007.00122.x
-
Herrstedt J, Dombernowsky P (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 101:143-150 (Pubitemid 47256390)
-
(2007)
Basic and Clinical Pharmacology and Toxicology
, vol.101
, Issue.3
, pp. 143-150
-
-
Herrstedt, J.1
Dombernowsky, P.2
-
11
-
-
44849134443
-
Chemotherapy-induced nausea and vomiting
-
DOI 10.1056/NEJMra0706547
-
Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-2494 (Pubitemid 351793021)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.23
-
-
Hesketh, P.J.1
-
12
-
-
0038372531
-
Olanzapine for intractable nausea in palliative care patients
-
Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliat Med 6:251-255 (Pubitemid 36538899)
-
(2003)
Journal of Palliative Medicine
, vol.6
, Issue.2
, pp. 251-255
-
-
Jackson, W.C.1
Tavernier, L.2
-
13
-
-
84869228161
-
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction
-
1:CAS:528:DC%2BC38XpvFCrsbg%3D 10.1016/j.jpainsymman.2011.10.023
-
Kaneishi K, Kawabata M, Morita T (2012) Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag 44:604-607
-
(2012)
J Pain Symptom Manag
, vol.44
, pp. 604-607
-
-
Kaneishi, K.1
Kawabata, M.2
Morita, T.3
-
14
-
-
34250810912
-
Cancer chemotherapy and cachexia: Mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects
-
1:STN:280:DC%2BD2szntFyhtw%3D%3D 10.1111/j.1365-2354.2006.00760.x
-
Kast RE, Foley KF (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care 16:351-354
-
(2007)
Eur J Cancer Care
, vol.16
, pp. 351-354
-
-
Kast, R.E.1
Foley, K.F.2
-
15
-
-
0022412283
-
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone
-
Kris MG, Gralla RJ, Clark RA, Tyson LB, Fiore JJ, Kelsen DP, Groshen S (1985) Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69:1257-1262 (Pubitemid 16217005)
-
(1985)
Cancer Treatment Reports
, vol.69
, Issue.11
, pp. 1257-1262
-
-
Kris, M.G.1
Gralla, R.J.2
Clark, R.A.3
-
16
-
-
0025192890
-
3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis
-
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821 (Pubitemid 20094145)
-
(1990)
New England Journal of Medicine
, vol.322
, Issue.12
, pp. 816-821
-
-
Marty, M.1
Pouillart, P.2
Scholl, S.3
Droz, J.P.4
Azab, M.5
Brion, N.6
Pujade-Lauraine, E.7
Paule, B.8
Paes, D.9
Bons, J.10
-
17
-
-
21644436404
-
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
-
DOI 10.1007/s00520-004-0755-6
-
Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529-534 (Pubitemid 40933610)
-
(2005)
Supportive Care in Cancer
, vol.13
, Issue.7
, pp. 529-534
-
-
Navari, R.M.1
Einhorn, L.H.2
Passik, S.D.3
Loehrer Sr., P.J.4
Johnson, C.5
Mayer, M.L.6
McClean, J.7
Vinson, J.8
Pletcher, W.9
-
18
-
-
34347369980
-
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study
-
DOI 10.1007/s00520-007-0248-5
-
Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15:1285-1291 (Pubitemid 47583449)
-
(2007)
Supportive Care in Cancer
, vol.15
, Issue.11
, pp. 1285-1291
-
-
Navari, R.M.1
Einhorn, L.H.2
Loehrer Sr., P.J.3
Passik, S.D.4
Vinson, J.5
McClean, J.6
Chowhan, N.7
Hanna, N.H.8
Johnson, C.S.9
-
19
-
-
82855171513
-
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial
-
1:CAS:528:DC%2BC3MXhsVWjsLbP 22024310 10.1016/j.suponc.2011.05.002
-
Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188-195
-
(2011)
J Support Oncol
, vol.9
, pp. 188-195
-
-
Navari, R.M.1
Gray, S.E.2
Kerr, A.C.3
-
20
-
-
84879149213
-
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
-
23314603 10.1007/s00520-012-1710-6
-
Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655-1663
-
(2013)
Support Care Cancer
, vol.21
, pp. 1655-1663
-
-
Navari, R.M.1
Nagy, C.K.2
Gray, S.E.3
-
21
-
-
0036286412
-
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain
-
DOI 10.1016/S0885-3924(02)00391-3, PII S0885392402003913
-
Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23:526-532 (Pubitemid 34627037)
-
(2002)
Journal of Pain and Symptom Management
, vol.23
, Issue.6
, pp. 526-532
-
-
Passik, S.D.1
Lundberg, J.2
Kirsh, K.L.3
Theobald, D.4
Donaghy, K.5
Holtsclaw, E.6
Cooper, M.7
Dugan, W.8
-
22
-
-
0037405988
-
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients
-
DOI 10.1016/S0885-3924(03)00078-2
-
Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, Beaver M, Comparet J, Brown J (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manag 25:485-488 (Pubitemid 36506679)
-
(2003)
Journal of Pain and Symptom Management
, vol.25
, Issue.5
, pp. 485-489
-
-
Passik, S.D.1
Kirsh, K.L.2
Theobald, D.E.3
Dickerson, P.4
Trowbridge, R.5
Gray, D.6
Beaver, M.7
Comparet, J.8
Brown, J.9
-
23
-
-
4744339480
-
A phase I trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: A hoosier oncology group study
-
DOI 10.1081/CNV-200029066
-
Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL, Loehrer P (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a hoosier oncology group study. Cancer Invest 22:383-388 (Pubitemid 39310908)
-
(2004)
Cancer Investigation
, vol.22
, Issue.3
, pp. 383-388
-
-
Passik, S.D.1
Navari, R.M.2
Jung, S.-H.3
Nagy, C.4
Vinson, J.5
Kirsh, K.L.6
Loehrer, P.7
-
24
-
-
0033135007
-
A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis
-
DOI 10.1016/S0002-9270(98)00337-2, PII S0002927098003372
-
Patterson D, Abell T, Rothstein R, Koch K, Barnett J (1999) A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94:1230-1234 (Pubitemid 29214634)
-
(1999)
American Journal of Gastroenterology
, vol.94
, Issue.5
, pp. 1230-1234
-
-
Patterson, D.1
Abell, T.2
Rothstein, R.3
Koch, K.4
Barnett, J.5
-
25
-
-
0033974902
-
Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: A case report
-
DOI 10.1002/(SICI)1099-1611(200001/02)9:1<84::AID-PON440>3.0.CO;2-T
-
Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84-87 (Pubitemid 30110394)
-
(2000)
Psycho-Oncology
, vol.9
, Issue.1
, pp. 84-87
-
-
Pirl, W.F.1
Roth, A.J.2
-
26
-
-
0025881104
-
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study
-
1:STN:280:DyaK3M3jtl2msQ%3D%3D 2031511 10.1097/00000421-199106000-00010
-
Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Santi E, Penza O, Ballatori E, et al. (1991) Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 14:238-242
-
(1991)
Am J Clin Oncol
, vol.14
, pp. 238-242
-
-
Roila, F.1
Boschetti, E.2
Tonato, M.3
Basurto, C.4
Bracarda, S.5
Picciafuoco, M.6
Patoia, L.7
Santi, E.8
Penza, O.9
Ballatori, E.10
-
27
-
-
79960435777
-
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States
-
1:CAS:528:DC%2BC3MXovFKmtbY%3D 21696263 10.1185/03007995.2011.596201
-
Schwartzberg L, Morrow G, Balu S, Craver C, Gayle J, Cox D (2011) Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Curr Med Res Opin 27:1613-1622
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 1613-1622
-
-
Schwartzberg, L.1
Morrow, G.2
Balu, S.3
Craver, C.4
Gayle, J.5
Cox, D.6
-
28
-
-
33645396238
-
Olanzapine use in cancer patients for refractory vomiting
-
1:CAS:528:DC%2BD28XjtFWktb4%3D 16531716
-
Shinjo T, Okada M (2006) Olanzapine use in cancer patients for refractory vomiting. Gan To Kagaku Ryoho 33:349-352
-
(2006)
Gan to Kagaku Ryoho
, vol.33
, pp. 349-352
-
-
Shinjo, T.1
Okada, M.2
-
29
-
-
0026443746
-
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy
-
1423181 10.1002/1097-0142(19921115)70:10<2524: AID- CNCR2820701022>3.0.CO;2-Z
-
Sledge GW Jr, Einhorn L, Nagy C, House K (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528
-
(1992)
Cancer
, vol.70
, pp. 2524-2528
-
-
Sledge, Jr.G.W.1
Einhorn, L.2
Nagy, C.3
House, K.4
-
30
-
-
0038054449
-
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer
-
DOI 10.1016/S0885-3924(03)00143-X
-
Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25:578-582 (Pubitemid 36629280)
-
(2003)
Journal of Pain and Symptom Management
, vol.25
, Issue.6
, pp. 578-582
-
-
Srivastava, M.1
Brito-Dellan, N.2
Davis, M.P.3
Leach, M.4
Lagman, R.5
-
31
-
-
0021359406
-
Intravenous metoclopramide: Prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation
-
Strum SB, McDermed JE, Pileggi J, Riech LP, Whitaker H (1984) Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. Cancer 53:1432-1439 (Pubitemid 14198909)
-
(1984)
Cancer
, vol.53
, Issue.6
, pp. 1432-1439
-
-
Strum, S.B.1
McDermed, J.E.2
Pileggi, J.3
-
32
-
-
17744370101
-
Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer
-
DOI 10.1007/s00520-004-0710-6
-
Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227 (Pubitemid 40576508)
-
(2005)
Supportive Care in Cancer
, vol.13
, Issue.4
, pp. 219-227
-
-
Sun, C.C.1
Bodurka, D.C.2
Weaver, C.B.3
Rasu, R.4
Wolf, J.K.5
Bevers, M.W.6
Smith, J.A.7
Wharton, J.T.8
Rubenstein, E.B.9
-
33
-
-
79953317123
-
Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting
-
19775450 10.1186/1756-9966-28-131
-
Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131
-
(2009)
J Exp Clin Cancer Res
, vol.28
, pp. 131
-
-
Tan, L.1
Liu, J.2
Liu, X.3
Chen, J.4
Yan, Z.5
Yang, H.6
Zhang, D.7
|